SuppreMol Appoints Industry Expert Klaus Schollmeier as CEO
Published: Apr 03, 2013
Dr. Schollmeier has more than 25 years of successful international management experience in the pharmaceutical and biotech industry as well as in investment banking. Dr. Schollmeier led Santhera Pharmaceuticals AG as CEO since the company’s foundation in 2004 and acts as Chairman of the Board since October 2011. Previously, he was Managing Director Healthcare / Biotechnology at ING BHF-Bank. Before this, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, US. His business functions included General Manager of BASF Pharma Netherlands and Vice President and General Manager for Western Europe. Mr. Schollmeier holds a Ph.D. in Biology from the University of Düsseldorf, Germany.
Dr. Thomas Hecht, Chairman of the Advisory Board of SuppreMol GmbH, said: "We are very pleased to have Dr. Schollmeier joining our Company at a time when SuppreMol is entering a new and exciting phase. The Company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr. Schollmeier will bring the necessary experience to the Company to advance SuppreMol’s products towards a BLA (Biologics License Application)." Dr. Hecht added: "On behalf of the Board I would like to thank Prof. Dr. Peter Buckel for his long-standing commitment to the success of SuppreMol and his valuable contributions in building the company over the past years."
“I look forward to leading SuppreMol in the exciting years to come. SuppreMol’s product candidates are based on innovative science and have shown promising data in early clinical trials ," stated Dr. Klaus Schollmeier, the Chief Executive Officer of SuppreMol GmbH. “I will lead the corporate and commercial development of SuppreMol in the years to come with the ambition to successfully advance the key assets, in particular the lead program SM101. ”
SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (Fc Rs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company’s lead product SM101, a recombinant soluble Fc RIIB is in phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol’s pipeline also includes two antibody development programs utilizing the inhibitory effect of Fc RIIB suitable for alternative treatment strategies and indications as well as an anti-IL-3 antibody to treat RA. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised € 40.3 million through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank , Bayern Kapital GmbH, Max Planck Society, and Z-Cube.
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680